These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26050492)

  • 1. [Twelve or thirty months of dual antiplatelet Therapy after drug-eluting stents. Results of the DAPT trial].
    Liakishev AA
    Kardiologiia; 2015; 55(1):57-8. PubMed ID: 26050492
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
    Sarafoff N; Martischnig A; Wealer J; Mayer K; Mehilli J; Sibbing D; Kastrati A
    J Am Coll Cardiol; 2013 May; 61(20):2060-6. PubMed ID: 23524219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
    Cornel JH; Ohman EM; Neely B; Clemmensen P; Sritara P; Zamoryakhin D; Armstrong PW; Prabhakaran D; White HD; Fox KA; Gurbel PA; Roe MT;
    Am Heart J; 2014 Jul; 168(1):76-87.e1. PubMed ID: 24952863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antiplatelet therapy after drug-eluting stents--how long to treat?
    Colombo A; Chieffo A
    N Engl J Med; 2014 Dec; 371(23):2225-6. PubMed ID: 25399657
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
    Goto S; Tomiya A
    Thromb Haemost; 2013 Feb; 109(2):177-8. PubMed ID: 23306954
    [No Abstract]   [Full Text] [Related]  

  • 7. Switching from prasugrel to clopidogrel: navigating in unknown waters.
    Angiolillo DJ; Rollini F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):166-8. PubMed ID: 23428008
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiplatelet therapy: risks and benefits of extended DAPT after stenting.
    Huynh K
    Nat Rev Cardiol; 2015 Jan; 12(1):1. PubMed ID: 25445134
    [No Abstract]   [Full Text] [Related]  

  • 9. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
    Garratt KN; Weaver WD; Jenkins RG; Pow TK; Mauri L; Kereiakes DJ; Winters KJ; Christen T; Allocco DJ; Lee DP
    Circulation; 2015 Jan; 131(1):62-73. PubMed ID: 25400062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial watch. DAPT study.
    Harv Heart Lett; 2010 Jan; 20(5):7. PubMed ID: 20217907
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.
    Silvano M; Zambon CF; De Rosa G; Plebani M; Pengo V; Napodano M; Padrini R
    J Thromb Thrombolysis; 2011 Feb; 31(2):233-4. PubMed ID: 21088983
    [No Abstract]   [Full Text] [Related]  

  • 14. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
    Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
    JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
    Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
    Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
    Beigel R; Fefer P; Rosenberg N; Novikov I; Elian D; Fink N; Segev A; Guetta V; Hod H; Matetzky S
    Am J Cardiol; 2013 Nov; 112(10):1551-6. PubMed ID: 23972349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The DAPT study].
    Pavasini R; Campo G; Limbruno U; De Servi S
    G Ital Cardiol (Rome); 2015; 16(7-8):393-8. PubMed ID: 26228607
    [No Abstract]   [Full Text] [Related]  

  • 20. Triple antithrombotic therapy with prasugrel in the stented patient: concern for more bleeding.
    Gurbel PA; Tantry US
    J Am Coll Cardiol; 2013 May; 61(20):2067-9. PubMed ID: 23524214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.